Original language | English (US) |
---|---|
Pages (from-to) | e709-e710 |
Journal | The Lancet Oncology |
Volume | 18 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2017 |
ASJC Scopus subject areas
- Oncology
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Go, no-go decision making for phase 3 clinical trials : ACT IV revisited – Authors' reply. / Weller, Michael; Butowski, Nicholas; Tran, David D.; Recht, Lawrence D.; Lim, Michael; Hirte, Hal; Ashby, Lynn; Mechtler, Laszlo; Goldlust, Samuel A.; Iwamoto, Fabio; Drappatz, Jan; O'Rourke, Donald M.; Wong, Mark; Hamilton, Mark G.; Finocchiaro, Gaetano; Perry, James; Wick, Wolfgang; Green, Jennifer; He, Yi; Turner, Christopher D.; Yellin, Michael J.; Keler, Tibor; Davis, Thomas A.; Stupp, Roger; Sampson, John H.
In: The Lancet Oncology, Vol. 18, No. 12, 12.2017, p. e709-e710.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Go, no-go decision making for phase 3 clinical trials
T2 - ACT IV revisited – Authors' reply
AU - Weller, Michael
AU - Butowski, Nicholas
AU - Tran, David D.
AU - Recht, Lawrence D.
AU - Lim, Michael
AU - Hirte, Hal
AU - Ashby, Lynn
AU - Mechtler, Laszlo
AU - Goldlust, Samuel A.
AU - Iwamoto, Fabio
AU - Drappatz, Jan
AU - O'Rourke, Donald M.
AU - Wong, Mark
AU - Hamilton, Mark G.
AU - Finocchiaro, Gaetano
AU - Perry, James
AU - Wick, Wolfgang
AU - Green, Jennifer
AU - He, Yi
AU - Turner, Christopher D.
AU - Yellin, Michael J.
AU - Keler, Tibor
AU - Davis, Thomas A.
AU - Stupp, Roger
AU - Sampson, John H.
N1 - Funding Information: MW reports grants and personal fees from Roche, Merck, Actelion, and Novocure; personal fees from MSD, Pfizer, Tocagen, Celldex, Magforce, Bristol-Myers Squibb; and grants from OGD2, Acceleron, and Bayer, outside the submitted work. DDT reports grants from Merck, Novartis, NWBio, Celldex, Stemline, VBL, and TVax; grants and personal fees from Novocure; personal fees from Monteris; and non-financial support from Corvidia, outside the submitted work. ML reports grants from Celldex, during the conduct of the study; grants from Regeneron; grants and personal fees from BMS and Agenus; and personal fees from Merck, Oncorus, Boston Biomedical, Stryker, and Baxter, outside the submitted work. SAG reports personal fees, non-financial support, and is a consultant and on the speaker's bureau and advisory board from Novocure; personal fees and non-financial support from Wex and Bristol-Myers Squibb; and personal fees from Cortice Biosciences, outside the submitted work. FI reports clinical trial costs from Celldex, during the conduct of the study; grants and personal fees from Merck and Novocure; and personal fees from Bristol Myers Squibb, Prime Oncology, Regeneron, AbbVie, and Alexion, outside the submitted work. DMO'R reports grants from Celldex Therapeutics, Inc, outside the submitted work and has issued patents. MW reports clinical trial costs from Celldex Therapeutics, Inc, during the conduct of the study. MGH reports personal fees from Celldex Therapeutics, Inc, during the conduct of the study. GF reports personal fees from BMS, outside the submitted work. WW reports grants and personal fees from MSD, grants and personal fees from Roche and BMS, outside the submitted work. JG, YH, CDT, MJY, TK, and TAD report personal fees, salary, and equity from Celldex Therapeutics, during the conduct of the study. RS reports fees (to institution) from MSD-Merck & Co, Roche/Genentech, Novartis, Merck KGaA, Darmstadt, AbbVie, and AstraZeneca, outside the submitted work; non-financial support from Novocure Ltd; and their spouse is a full-time employee of Celgene and has equity in Celgene. JHS reports stock from Istari Oncology; stock from Annais; personal fees from Bristol-Myers Squibb; personal fees and consulting and stock options from Immunomic Therapeutics; and patents with royalties paid. NB, LDR, HH, LA, LM, JD, and JP declare no competing interests.
PY - 2017/12
Y1 - 2017/12
UR - http://www.scopus.com/inward/record.url?scp=85035348037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85035348037&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(17)30856-2
DO - 10.1016/S1470-2045(17)30856-2
M3 - Letter
C2 - 29208433
AN - SCOPUS:85035348037
VL - 18
SP - e709-e710
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 12
ER -